- Company
- CKD aims at developing next-generation·new anti-cancer drug
- by Son, Hyung Min Aug 26, 2025 06:06am
- Chong Kun Dang is speeding up investment in the new anti-cancer drug sector. The company aims to commercialize anti-cancer drugs by advancing its in-house pipelines for Antibody-Drug Conjugates (ADCs) and Cell and Gene Therapies (CGTs). Additionally, Chong Kun Dang is securing domestic rights for new drugs, including Chimeric Antigen Receptor T-
- Policy
- MFDS will intensively monitor Wegovy and other obesity drugs
- by Lee, Hye-Kyung Aug 26, 2025 06:05am
- The Ministry of Food and Drug Safety (MFDS) has designated ‘Wegovy’ and other GLP-1-class obesity injectables as targets for intensive monitoring and plans to continuously monitor side effects in collaboration with the Korea Institute of Drug Safety & Risk Management. Th MFDS designates the intensive monitoring status to drugs with high
- Company
- Expanded indication for Kisqali in early breast cancer
- by Son, Hyung Min Aug 26, 2025 06:05am
- On August 22, Novartis Korea (CEO and President Byeong-jae Yoo) announced that its CDK 4/6 inhibitor, Kisqali, was approved for a new indication from the Ministry of Food and Drug Safety for use as an adjuvant therapy in patients with HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) Stage II and III e
- Company
- Will companies pass Korea due to Trump’s drug price reform?
- by Moon, sung-ho Aug 26, 2025 06:05am
- Since Trump took office, the US has designated the pharmaceutical industry as its core strategic industry and is working to reshape the industry with the US at its center. The goal is to significantly lower drug prices in the U.S., the world's largest pharmaceutical market. However, the “Most-Favored-Nation Pricing (MFN)” policy recently a
- Company
- Expanded competitiveness of K-Bio immunotherapies
- by Son, Hyung Min Aug 26, 2025 06:05am
- Korean pharmaceutical and biotech companies are entering the development of immunotherapies, increasing the possibility of 'big deals' with global pharmaceutical companies. As competition for new drugs targeting next-generation immune checkpoint proteins intensifies, Aprogen has begun developing VISTA targets by securing an antibody candidate fr
- Company
- Jaypirca may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho Aug 26, 2025 06:04am
- The BTK inhibitor Jaypirca may now be prescribed in general hospitals in Korea. According to industry sources on the 22nd, Lilly Korea’s relapsed and refractory mantle cell lymphoma treatment Jaypirca (pirtobrutinib) has passed review of Drug Committees (DCs) at medical institutions in Korea, including Samsung Medical Center, Pusan Unive
- Policy
- SK chemicals' Afstyla will be removed from the reimb list
- by Lee, Tak-Sun Aug 25, 2025 06:08am
- SK chemicals' hemophilia A treatment, Afstyla, which was out-licensed by the company, will be removed from the reimbursement list due to a lack of record of supply performance. The product's delisting was previously deferred in 2023 through conditional negotiation, but with no sales to show since, the decision to remove it has become fina
- Company
- 'New treatment opportunities rise for acquired hemophilia A'
- by Whang, byung-woo Aug 25, 2025 06:06am
- There is an extremely rare bleeding disorder that affects one in every 100,000 people. It is acquired hemophilia A, a condition in which healthy individuals experience unexplained bruising and severe bleeding throughout the body. Until recently, there were limited treatment options available for emergencies, causing significant challenges for
- Policy
- NHIU ‘Eradicate rebates with INN-based prescriptions'
- by Lee, Tak-Sun Aug 25, 2025 06:06am
- The National Health Insurance Trade Union stressed the need to eradicate pharmaceutical rebates by improving the drug pricing system and distribution structure to those of advanced country standards. The union also advocated the introduction of generic substitution through international nonproprietary name prescriptions. On the 18th, it wa
- Policy
- IV formulation of Korea’s first IL-23 drug Tremfya approved
- by Lee, Hye-Kyung Aug 25, 2025 06:05am
- The intravenous injection formulation of Tremfya, the first interleukin-23 (IL-23) inhibitor in Korea, was recently granted approval, paving the way for the supply of all Tremfya injection formulations in Korea. On the 21st, the Ministry of Food and Drug Safety approved Janssen Korea's Tremfya Intravenous Injection (guselkumab, recombina
